There are 2789 resources available
638P - Evaluating the contribution of virtual peer-led support to comprehensive prostate cancer (PCa) care: The AnCan experience
Presenter: Herbert Geller
Session: ePoster Display
640TiP - Phase Ib/II trial of pembrolizumab (pembro) + lenvatinib combination therapy in patients (pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts E and F
Presenter: Gero Kramer
Session: ePoster Display
641TiP - Phase Ib/II trial of pembrolizumab (pembro) + vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H
Presenter: Johann de Bono
Session: ePoster Display
642TiP - Phase II CA184-585 (INSPIRE) trial of ipilimumab with nivolumab for molecular-selected patients with castration-resistant prostate cancer
Presenter: Niven Mehra
Session: ePoster Display
643TiP - Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors
Presenter: Hendrik-Tobias Arkenau
Session: ePoster Display
646TiP - A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse: The PEACE 2 trial from Unicancer
Presenter: Pierre Blanchard
Session: ePoster Display